-
Significant progress! The combined use of three strategies results in a nearly 100% response rate to cancer treatment
Time of Update: 2021-02-12
In a new study, researchers from Massachusetts General Hospital, New Jersey State University and Rush University Medical Center found that combining three advanced strategies for treating malignant melanoma ---promole-targeted therapy, immune checkpoint blocking, and the use of lysomavirus--- could significantly improve outcomes.
-
Science Advances: Significant progress! Yanbian University and other multi-unit cooperation, found a new intervention strategy for colitis.
Time of Update: 2020-10-27
October 21, 2020, Zhang Qingxuan of Yanbian University, Wu Yuzhang of the Army Military Medical University, Chen Yongwen and Huang Jian, Chongqing Emergency Medical Center/Chongqing University Affiliated Center Hospital (Yanbian University is the first unit), published online on Science with the title "CD1d1 intrinsic Signaling" In a study paper by in macrophages controls NLRP3 inflammasome expression whenitis, the study found that CD1d1 deficiency or CD1d1 specific missing mice in macrophages (LymCD1d1-/-) were resistant to DSS-induced acute colitis.
-
Sci Transl Med: Significant progress! Wang Hongyang's team reveals new strategies for precision treatment of bile tube cancer.
Time of Update: 2020-10-04
Through a series of screening and clinical studies have found that the use of multiple myeloma treatment drug Bortzomib can significantly inhibit the growth of these bile tube cancer cells; The work found that the anti-cancer gene PTEN regulates protease activity, clarifies its signal transducting pathway, and puts forward a new strategy for accurate target diagnosis and treatment of bile tube cancer, which is of great clinical significance and a fine example of translational medicine research.
-
Significant results of drug review reform, comparison of antibody review strategies in China, the United States and the European Union
Time of Update: 2020-06-15
Texts Drug consulting Guo Lei team from 1975 hybrid tumor technology was born, until 1986 the first antibody drug OKT3 was born Since then, more than 30 years later, antibody medicine has gradually
-
Significant achievements in drug review reform Comparison of antibody review strategies between China, the United States and the European Union
Time of Update: 2020-06-05
From 1975, the hybrid tumor technology was born until the birth of the first antibody drug OKT3 in 1986 Since then, more than 30 years, antibody drugs have gradually become an indispensable force in t
-
Significant achievements in drug review reform Comparison of antibody review strategies between China, the United States and the European Union
Time of Update: 2020-06-05
From 1975, the hybrid tumor technology was born until the birth of the first antibody drug OKT3 in 1986 Since then, more than 30 years, antibody drugs have gradually become an indispensable force in t